Member Info for GreenManDK

I just chased up LSE for an update on fixing the missing RNS and got this response, sounds like it won’t be fixed anytime soon:

“The issue sits with the data supplier unfortunately. Our director has raised the issue multiple times and hopefully they'll be able to permanently fix the problem sooner rather than later.”

Another great RNS

https://faron.com/releases-and-publications/farons-bexmarilimab-demonstrates-immune-activating-and-drug-sensitizing-potential-in-myeloid-malignancies/

Very exciting!!

Hmmm, I think partnership deal must be a long way off

If you genuinely think that then by all means please go to the races, each to their own

Because all this news was priced in as we saw very positive interim data releases. Catalyst will be partnership or M&A announcement. Even the considerable funds we have at the moment aren’t enough for a p3 trial so something major will have to emerge in one way or another

And another RNS this morning that LSE have failed to publish:

https://faron.com/releases-and-publications/faron-announces-acceptance-of-bexmarilimab-data-for-oral-presentation-at-eha-2025-congress/

Annoying that LSE still haven’t fixed the RNS problem but if you missed it it’s here;

https://faron.com/releases-and-publications/faron-pharmaceuticals-ltd-grant-of-options/

Anyone with a good scientific understanding able to differentiate this data from the initial p2 data announcement?

Yes we did, it just wasnt published on here as this site has issues with RNS notifications for Faron. Here is the announcement, the results were in line with the positive expectations!

https://faron.com/releases-and-publications/inside-information-faron-announces-positive-phase-ii-results-in-higher-risk-myelodysplastic-syndrome/

Also there is this:

https://faron.com/investors/faron-as-an-investment/strategy/

From an industry perspective I believe its green light for phase 3 from the FDA and from a company perspective I believe its releasing the detailed data and analysis from Phase 2 for the upcoming conference and agreeing a partnership with a major pharma player.

I think most people on this board will sell into partner news which should hopefully have rebased the stock price significantly. I will probably leave something on the table to see where this goes long term. I’ve been invested here since 2018 and have built an overly large position so partner news will be the catalyst to reset my portfolio

Https://www.redeye.se/research/1098753/faron-pharmaceuticals-250425?utm_source=interview&utm_medium=email

Glad to read that it wasn't Timo selling out, that would have been a real confidence knock, as Bmhltd suggested earlier. Good rational for sale, momentum already reversed!

Faron Pharmaceuticals Ltd | Company announcement | April 17, 2025 at 15:15:00 EEST

Holding in Company

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces that, on 16 April 2025, A&B (HK) Company Ltd (“A&B”) divested its entire shareholding of 3,559,893 ordinary shares representing approximately 3.40% of the Company’s issued share capital.

A&B (HK) Company Ltd, an investment and development company based in Hong Kong, initially invested in the Company in 2015. This investment was part of a strategic agreement involving Faron’s lead drug candidate, Traumakine®, which was developed for the treatment of moderate to severe acute respiratory distress syndrome (ARDS). As Faron’s focus is on the development of its lead asset, bexmarilimab, this strategic investment by A&B no longer serves its original purpose and as such, A&B sold its holding and created a significant increase in the liquidity of Faron’s shares in the market.

For more information please contact:

IR Partners, Finland (media)

Riina Tuominen

+358 44 313 5005

Https://www.redeye.se/research/1095390/faron-pharmaceuticals-positive-phase-ii-bexmab-topline-results?utm_source=report&utm_medium=email¬ificationId=5fa01867-94eb-4abe-839b-ff79ca86b23f

I messaged LSE this morning regarding the missing RNS and they responded with this:

Thank you for your email. The technical team are resolving the issue currently so hopefully the releases will show soon once the data supplier sends them over.

Kind regards,

Craig

London South East

www.LSE.co.uk

Agreed, but that’s on a much longer timeframe

I reckon it'll be Monday 28th